Medix Biochemica has acquired 100 percent of the shares of USA-based Bioresource Technology (BRT), a leading provider of base matrices for the in vitro diagnostics ("IVD") manufacturing industry worldwide.  

As a result of the acquisition, the highly complementary portfolios of BRT and Medix Biochemica now provide a complete offering of critical raw materials for IVD quality control (QC) products which will be available through Medix Biochemica’s comprehensive global sales network. 

The acquisition is another important step in the execution of Medix Biochemica’s strategy to be the first-choice raw material partner to the IVD industry and help customers’ goal to further consolidate their supply chain.

Medix Biochemica has acquired 100 percent of the shares of Bioresource Technology ("BRT") to broaden its base matrix capabilities and further strengthen its local presence in the US market.

As a result of this partnership, Medix Biochemica will provide its customers with a comprehensive offering of raw materials for their IVD quality control products. The organization and operations of BRT will form a significant part of Medix Biochemica’s IVD Biomaterials Business Unit, which also comprises manufacturing of native antigens, enzymes, proteins and biologicals in St. Louis, Missouri.

BRT’s operations will stay in Weston, Florida, and BRT’s President Derik Reichenbach and CEO Ron Dilling will remain as strategic advisors following the acquisition.  

"Together, we have the potential to broaden our offering to IVD companies across the globe. There is an excellent complementary offering between our portfolios, enabling Medix Biochemica to be a comprehensive partner for IVD companies requiring quality raw materials for QC products. With our complete offering of biological samples, processed plasma, base matrices, native enzymes, proteins, antibodies or antigens and our depth of expertise, we can dramatically reduce time to market for IVD companies whatever their need. Our vision is to be the first-choice partner for the IVD industry, and the team at BRT takes us one step closer," says Steve Ferguson, CEO of Medix Biochemica. 

"We are excited about joining Medix Biochemica", says Derik Reichenbach, President of BRT. "Building long-term relationships with our customers have always been key to our success and together with Medix Biochemica’s global team, we are now able to reach even more IVD customers across the globe. We are very much looking forward to contributing to the strong growth of Medix Biochemica".